pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
BioPharma Dive·1h ago·1 min read
save

Labor Dept finalizes PBM disclosure rule to boost transparency for self-insured employers

Oct 29, 2026·read at BioPharma Dive ↗RegulatoryNeutral

The U.S. Labor Department has finalized a rule that will require pharmacy benefit managers to disclose detailed fee and compensation information to self-insured employer clients, with the requirement taking effect in July 2027.

The rule mandates that PBMs reveal payments received from drugmakers, pharmacies and other supply-chain entities, including negotiated rebates and "spread" payments that arise when a plan’s reimbursement exceeds what the PBM pays a pharmacy. Disclosures must be provided during contract negotiations or renewals and updated every six months, with employers allowed an annual audit.

Regulators estimate the transparency could lower drug costs for employers and workers by about $22 billion over ten years. Employers have welcomed the move, while PBMs have criticized it as government overreach and warned of severe penalties for non-compliance.

source

This writeup was produced by pharmadog from original reporting by BioPharma Dive.

Original headline: “Labor Department finalizes sweeping PBM disclosure rule”

read at BioPharma Dive ↗
1,109 words · retrieved 38m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
HOOKIPA Pharma Inc.RISING

related stories

  • May 13Extreme heat is worsening faster for Black AmericansSTAT
  • May 13STAT+: A new kind of liver crisis is emerging in the U.S. The American diet is to blameSTAT
  • May 13Opinion: Access to air conditioning is critical preventive care. But federal policy treats it as optionalSTAT
  • May 12Supreme Court extends mifepristone deadlineSTAT
  • May 12Second Clinical Scenario - Progressive Disease Despite Hematocrit Controlonclive